Axsome Therapeutics Reports Positive Alzheimer Results
Axsome Therapeutics Inc. (AXSM) reported that its lead drug candidate AXS 05 met its primary endpoint in the ADVANCE-1 Phase 2/3 trial. The ADVANCE-1 study was a randomized, double-blind, controlled, trial and had 366 patients suffering from Alzheimer’s disease. Currently, there is no FDA approved treatment in Alzheimer’s disease agitation, which is the most common form of dementia.
AXS-05 met the primary endpoint by showing a statistically significant mean reduction in the Cohen Mansfield Agitation Inventory ((CMAI)) total score compared to placebo at Week 5. The mean